Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.45 |
| ▸ | CCR5 | P51681 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8171722 | 1.00 | HTT (0.55) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13205421 | 0.89 | SMN1; SMN2 (0.53) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2804464 | 0.89 | SMN1; SMN2 (0.55) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2804463 | 0.89 | SMN1; SMN2 (0.55) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2363233 | 0.83 | HTT (0.53) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2806846 | 0.83 | SMN1; SMN2 (0.47) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL4016879 | 0.83 | SMN1; SMN2 (0.47) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL13012605 | 0.82 | SMN1; SMN2 (0.57) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL9237582 | 0.81 | ENPP2 (0.50) | HTTCCR5MEN1KMT2A | |
| SCHEMBL24359316 | 0.81 | SMN1; SMN2 (0.61) | HTTSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299271-B2 | Solid tartrate salts of DPP-IV inhibitors | PHENOMIX CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100323988-A1 | SOLID CITRATE AND TARTRATE SALTS OF DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-7786312-B2 | Methods of preparing heterocyclic boronic acids and derivatives thereof | PHENOMIX CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786312-B2 | Methods of preparing heterocyclic boronic acids and derivatives thereof | PHENOMIX CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100087658-A1 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087658-A1 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2009094462-A1 | A CRYSTALLINE SYNTHETIC INTERMEDIATE FOR PYRROLIDIN-3-YL-GLYCYLAMINOALKYLBORONATES | PHENOMIX CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20080300413-A1 | Methods of Preparing Hetercyclic Boronic Acids and Derivatives Thereof | SINO-MED INTERNATIONAL ALLIANCE, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300413-A1 | Methods of Preparing Hetercyclic Boronic Acids and Derivatives Thereof | SINO-MED INTERNATIONAL ALLIANCE, INC. | 2008-12-04 | — | — | US | disclosed |
| WO-2008109681-A2 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | PHENOMIX CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300413-A1 | Methods of Preparing Hetercyclic Boronic Acids and Derivatives Thereof | HLCS, NISCH, BTD | HTT 226/4885SMN1; SMN2 2610/4885NPC1 1901/4885 |
| US-20100087658-A1 | METHODS AND INTERMEDIATES FOR SYNTHESIS OF SELECTIVE DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | HTT 3246/4885SMN1; SMN2 3932/4885NPC1 2124/4885 |
| US-20100323988-A1 | SOLID CITRATE AND TARTRATE SALTS OF DPP-IV INHIBITORS | DPP4, DPP3, DPP7 | HTT 2314/4885SMN1; SMN2 4631/4885NPC1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.